AUS
NZ
UK
CA
USA
IND
Highlights
- BioVie Inc. launches a registered direct offering, issuing shares at a set price.
- The company is also issuing unregistered warrants in a concurrent private placement.
- Proceeds will support working capital and general corporate purposes.
BioVie Inc., a company operating in the Healthcare sector, has announced a new registered direct offering. This offering involves issuing shares of common stock and unregistered warrants in a concurrent private placement. BioVie focuses on the development of treatments for chronic diseases, including neurological and liver conditions.
Details of the Direct Offering
BioVie (NASDAQ:BIVI) has set the terms of its registered direct offering, pricing shares of its common stock. Alongside this, the company is issuing unregistered warrants that are tied to the concurrent private placement. These warrants will be exercisable after a specific period and are set to expire five years from their initial exercise date.
The company plans to close the offering around October 22, 2024. ThinkEquity, a financial services firm, is acting as the sole placement agent for this transaction. The offering is conducted under a shelf registration statement that BioVie previously filed with the U.S. Securities and Exchange Commission (SEC).
Purpose of the Offering
BioVie has indicated that the proceeds from this offering will be utilized for working capital and general corporate purposes. This move is part of the company’s broader strategy to secure additional funds to support its ongoing operations and development projects. By raising capital through this offering, BioVie aims to maintain its momentum in advancing its treatment programs and managing operational requirements.
Structure of the Private Placement
In addition to the shares issued through the direct offering, BioVie is also conducting a concurrent private placement. This aspect of the offering involves issuing unregistered warrants, which provide the holder with the right to purchase additional shares at a set price. The warrants will become exercisable after a six-month period and have a fixed duration of five years from the initial exercise date.
The structure of this private placement is designed to offer flexibility for future capital raising while also ensuring that investors have a long-term interest in the company’s performance. This combination of direct offering and private placement reflects a strategic approach to strengthening BioVie’s financial position.
Regulatory Compliance and Market Presence
As part of its regulatory compliance, BioVie has conducted the offering under a shelf registration statement that was already filed with the SEC. This ensures that the company adheres to necessary guidelines, providing transparency and maintaining investor confidence.
By issuing new shares and warrants, BioVie continues to engage with the market, aiming to bolster its presence and reinforce its capacity to sustain operations. This initiative aligns with its commitment to expanding its capabilities and furthering its therapeutic developments.
